Cystatin-C is a sensitive marker of renal impairment with an independent predictive value for survival in multiple myeloma; Reduction post bortezomib monotherapy

被引：1
|
作者：
Terpos, Evangelos
Katodritou, Eirini
Tsiftsakis, Evangelos
Kastritis, Efstathios
Pouli, Anastasia
Christoulas, Dimitrios
Michali, Evridiki
Verrou, Evgenia
Banti, Anastasia
Tsionos, Konstantinos
Dimopoulos, Meletios A.
Zervas, Konstantmos
机构：
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1484
引用
收藏
页码：444A / 444A
页数：1
相关论文
共 24 条
  • [1] Cystatin-C: An early marker of renal impairment and an independent predictive factor for survival in multiple myeloma. Reduction post bortezomib
    Terpos, E.
    Katodritou, E.
    Tsiftsakis, E.
    Verrou, E.
    Christoulas, D.
    Anagnostopoulos, A.
    Banti, A.
    Pouli, A.
    Tsionos, K.
    Dimopoulos, M. A.
    Zervas, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 118 - 118
  • [2] Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration
    Terpos, Evangelos
    Katodritou, Eirini
    Tsiftsakis, Evangelos
    Kastritis, Efstathios
    Christoulas, Dirnitrios
    Pouli, Anastasia
    Michalis, Eurydiki
    Verrou, Evgenia
    Anargyrou, Konstantinos
    Tsionos, Konstantinos
    Dimopoulos, Meletios A.
    Zervas, Konstantinos
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (03): : 372 - 379
  • [3] CYSTATIN-C AS A MARKER FOR RENAL IMPAIRMENT IN PREECLAMPSIA
    Niraula, A.
    Lamsal, M.
    Baral, N.
    Majhi, S.
    Khan, S.
    Basnet, P.
    NEPHROLOGY, 2016, 21 : 63 - 63
  • [4] Clinical implications and predictive value of the creatinine-cystatin C ratio in patients with multiple myeloma and renal impairment
    Sun, Yixuan
    Zhao, Junfeng
    Du, Jiachen
    Li, Ying
    Ding, Fangjie
    Zhao, Wenbo
    ONCOLOGY LETTERS, 2024, 27 (03)
  • [5] Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Cystatin-C Are Sensitive Markers of Renal Injury in Patients with Multiple Myeloma
    Terpos, Evangelos
    Papassotiriou, Gerasimos-Petros
    Kastritis, Efstathios
    Gkotzamanidou, Maria
    Christoulas, Dimitrios
    Eleutherakis-Papaiakovou, Evangelos
    Margeli, Alexandra
    Migkou, Magdalini
    Gavriatopoulou, Maria
    Roussou, Maria
    Papassotiriou, Ioannis
    Dimopoulos, Meletios Athanasios
    BLOOD, 2011, 118 (21) : 1676 - 1676
  • [6] CYSTATIN-C, ALIAS POST-GAMMA-GLOBULIN - A MARKER FOR MULTIPLE-SCLEROSIS
    BOLLENGIER, F
    JOURNAL OF CLINICAL CHEMISTRY AND CLINICAL BIOCHEMISTRY, 1987, 25 (09): : 589 - 593
  • [7] Cystatin-C a sensitive diagnostic marker for evaluation of the renal function in patients with cisplatin based chemotherapy
    Boelke, E.
    Matuschek, C.
    Peiper, M.
    Giro, C.
    Pelzer, M.
    Budach, W.
    Gripp, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Evaluation of serum Cystatin-C as a prognostic and predictive factor in patients with newly diagnosed multiple myeloma.
    Reddy, Rakesh
    Gupta, Ritu
    Mathur, Nitin
    Rani, Lata
    Sharma, Atul
    Kumar, Lalit
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Reversibility of Renal Impairment of Multiple Myeloma Patients Treated with Bortezomib-Based Regimens: Identification of Predictive Factors
    Dimopoulos, Meletios A.
    Roussou, Maria
    Kastritis, Efstathios
    Gavriatopoulou, Maria
    Zagouri, Flora
    Migkou, Magdalini
    Matsouka, Charis
    Barmparousi, Despina
    Christoulas, Dimitrios
    Psimenou, Erasmia
    Grapsa, Irini
    Terpos, Evangelos
    BLOOD, 2008, 112 (11) : 607 - 608
  • [10] Reversibility of Renal Impairment in Patients With Multiple Myeloma Treated With Bortezomib-Based Regimens: Identification of Predictive Factors
    Dimopoulos, Meletios A.
    Roussou, Maria
    Gavriatopoulou, Maria
    Zagouri, Flora
    Migkou, Magdalini
    Matsouka, Charis
    Barbarousi, Despina
    Christoulas, Dimitrios
    Primenou, Erasmia
    Grapsa, Irini
    Terpos, Evangelos
    Kastritis, Efstathios
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (04): : 302 - 306
123